TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07266428: A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

Sponsor: Ottimo Pharma Limited · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 170 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$2,788,170

Rescue Site Savings

+$1,845,690

Unlock Full NCT07266428 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07266428 Rescue Dossier →